Table 3.
Clinical details of healthy control subjects and patient with AATD cohorts either receiving or not receiving AAT augmentation therapy from Icahn School of Medicine at Mount Sinai
| Healthy controls | AATD without augmentation therapy | AATD with augmentation therapy | P value | |
| Number of samples | 8 | 6 | 6 | |
| Age, years (mean±SD) | 49.1±13.3 | 53.3±12.2 | 54.3±8.6 | 0.6798 |
| Gender (male/female) | 5/3 | 3/3 | 4/2 | 0.9845 |
| Baseline plasma AAT (μM) | 25.2±5.0 | 6.7±3.4 | 14.5±2.8 | <0.0001 |
| Former smokers (%) | 0 | 83.3 | 83.3 | 0.0022 |
| FEV1 % predicted (%) | – | 55.3±20.5 | 51.4±15.7 | 0.5655 |
| FVC % predicted (%) | – | 86.3±12.3 | 84.4±13.3 | 0.7218 |
| FEV1/FVC % (%) | – | 55.3±20.5 | 51.2±9.3 | 0.5203 |
| DLCO % predicted (%) | – | 61.3±16.9 | 57.3±15.2 | 0.6757 |
Six patients were receiving plasma purified AAT from CSL Behring (Zemaira). HC and patient samples were employed in figure 5B and figure 7B–F. For AATD five out of six samples were used for mRNA and three out of six samples were used for protein expression, determined by sample availability. Descriptive statistical comparisons by groups performed and p values shown.
DLCO, diffusing capacity of lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity (% predicted).